entertainment
Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.
Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.
advertisement
Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
